Phillips-Medisize Expands - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Phillips-Medisize Expands



Phillips-Medisize, an outsource provider of design and manufacturing services for medical devices and drug delivery markets, reports the start of production and completion of the 60,000-ft2expansion to its Kontiolahti, Finland site. Production has already begun and will continue to ramp up several new programs before the first of the year. The site focuses on the industrialization and production of inhalers, insulin pens, transfer devices, and syringes.

The expansion includes 12,900 ft2 of Class 8 clean-room manufacturing and assembly and has space for the additional expansion for molding machines and assembly. New high-speed automation lines enable the ramp up of multi-component, complex drug-delivery devices from prototype to high-speed automated 24/7 mass production under competitive cost-structure. Total Kontiolahti numbers now include, multiple high-speed, fully automated assembly lines, fully automated printing lines, and several semi-automated lines.

Source: Phillips-Medisize

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here